Jobs / United States / Astrazeneca Pharmaceuticals Lp
Global MSL Excellence Director
Astrazeneca Pharmaceuticals Lp · 🇺🇸 US - Gaithersburg - MD
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Astrazeneca Pharmaceuticals Lp paid sponsored hires in similar roles1 certified filing for “Global Product Teams Finance Director, R&D Finance” (Financial Managers) in MD: $196k–$196k, median $196k. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Astrazeneca Pharmaceuticals Lp
The US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Astrazeneca Pharmaceuticals Lp →
About the role
The Oncology Global MSL Excellence Director is accountable for defining the oncology tumour-area specific Field Medical strategy and overseeing the effective delivery of key MSL excellence initiatives that strengthen MSL capabilities across AZ regions for the Oncology Business Unit. Relying on extensive Field Medical leadership and tumour area expertise, the GMSLE Director operates as the main point of contact for the tumour area – acting as the subject matter expert for Field Medical and providing consultation on all MSL-related activities. The Global MSL Excellence Director is accountable for leading the Field Medical Leadership Team to drive high-impact operational and engagement excellence across markets, ensuring the robust adoption of enterprise Field Medical standards, delivering programmes to build Oncology-specific Field Medical capabilities, and shaping the future Field Medical role in Oncology. The GMSLE Director collaborates closely with Global Medical Affairs, Global Clinical Operations, Global Medical Excellence, Strategy and Operations (MESO), in-market Field Medical leadership and other cross-functional partners to ensure Field Medical strategy and MSL effort allocation aligns with Global tumour area priorities and Local needs ACCOUNTABILITIES Field Medical strategy: • Accountable for setting and governing the overarching tumour area Field Medical strategy and 12–24 month roadmap across the portfolio - anchored to Global medical strategy, scientific narrative(s), care gaps, evidence milestones, launch and external engagement needs, and translated into clear priorities and success measures for markets. • Accountable for leading the Field Medical Leadership Team (FMLT), driving localisation and operationalisation of Field Medical strategy and MSL activities in line with tumour area priorities and Local needs. Tactical planning and execution: • Accountable for the strategic alignment and integration of plans across all tumour area Field Medical tactics; overseeing the continuous tracking and reporting of measurable success criteria, budget and timelines. • Monitor delivery by Associate Directors and affiliates; maintaining accountability for the adaptation of plans according to evolving priorities, escalating challenges/risks and potential solutions to tumour area and/or functional leadership. Cross-functional partnering: • Acts as primary point of contact for GMSLE in the tumour area, accountable for representing Field Medical in cross-functional Global/Regional forums. • Ensures close collaboration with key stakeholders – including Global Medical Affairs, Clinical Operations, Medical Excellence, Strategy & Operations (MESO), Local Field Medical and Alliance stakeholders (amongst others) – to align Field Medical strategy to tumour area priorities and Local needs. Clinical trial operations: • Lead the collaboration with Global Clinical Operations, Global Medical Affairs and Local Markets for Field Medical support of AstraZeneca’s clinical development program – embedding study prioritisation governance, communicating clear expectations for Field Medical support and proactively addressing Global/Local challenges to facilitate the effective delivery of our trials with measurable impact. Insights strategy and reporting: • Accountable for ensuring Field Medical insights priorities, external engagement strategy and quality standards align to Global Medical strategy and market needs – whilst influencing consistent adoption across regions. • Accountable for the timely Global-to-Local cross-functional discussion and leadership escalation of key insights themes and recommendations, ensuring findings inform tumour area strategy, evidence plans and launch decisions – includi